




SUPPLEMENTARY FIGURES




Supplementary Figure 1. AGTR1 is highly expressed in ER+ or HER2- tumour tissues. (A) The tumour samples with different ER and HER2- statuses were subjected to immunohistochemical staining with anti-AGTR1. (B) HSCORE of AGTR1 protein expression in breast cancer tissues with different ER and HER2 statuses. **, P<0.01; ***P<0.001. (C) Relative amount of AGTR1 mRNA in cancer tissues with different ER and HER2 statuses in the TCGA database. ***, P<0.001.




Supplementary Figure 2. AGTR1 expression in breast cancer cells. (A) AGTR1 mRNA and (B) protein expression in MDA-MB-231, MDA-MB-468, MCF-7, T47D and SKBR3 breast cancer cells.




Supplementary Figure 3. Level of VEGF-C mRNA in MDA-MB-231 and 4T1 mouse tumours.




Supplementary Figure 4. Level of CCL21 mRNA in MDA-MB-231 and 4T1 mouse lymph nodes.




Supplementary Figure 5. MDA-MB-231 cell viability after treatment with different concentrations of LOS (0, 5, 10, 50 μ M) by CCK8.




Supplementary Figure 6. MCF7 cell viability after treatment with different concentrations of LOS (0, 5, 10, 50 μM) by CCK8.



Supplementary Figure 7. HBL-100 cell viability after treatment with different concentrations of LOS (0, 100, 200, 300 μM) by CCK8.



Supplementary Figure 8. MOCK and AGTR1^{high} cell apoptosis with LOS 100 μ M.



Supplementary Figure 9. MOCK and AGTR1^{high} cell cycle with LOS 100 μ M.